Antibody Profiling of Dengue Severities Using Flavivirus Protein Microarrays

Dengue is a viral disease transmitted by Aedes aegypti mosquitoes. According to the World Health Organization, about half of the world's population is at risk of dengue. There are four serotypes of the dengue virus. After infection with one serotype, it will be immune to such a serotype. Howeve...

Celý popis

Uložené v:
Podrobná bibliografia
Vydané v:Analytical chemistry (Washington) Ročník 95; číslo 41; s. 15217
Hlavní autori: Tsai, Pei-Shan, Du, Pin-Xian, Keskin, Batuhan Birol, Lee, Nan-Yao, Wan, Shu-Wen, Lin, Ya-Lan, Su, Wen-Yu, Lin, Pei-Chun, Lin, Wei-Hsun, Shih, Hsi-Chang, Ho, Tzong-Shiann, Syu, Guan-Da
Médium: Journal Article
Jazyk:English
Vydavateľské údaje: 17.10.2023
ISSN:1520-6882, 1520-6882
On-line prístup:Zistit podrobnosti o prístupe
Tagy: Pridať tag
Žiadne tagy, Buďte prvý, kto otaguje tento záznam!
Abstract Dengue is a viral disease transmitted by Aedes aegypti mosquitoes. According to the World Health Organization, about half of the world's population is at risk of dengue. There are four serotypes of the dengue virus. After infection with one serotype, it will be immune to such a serotype. However, subsequent infection with other serotypes will increase the risk of severe outcomes, e.g., dengue hemorrhagic fever, dengue shock syndrome, and even death. Since severe dengue is challenging to predict and lacks molecular markers, we aim to build a multiplexed Flavivirus protein microarray (Flaviarray) that includes all of the common Flaviviruses to profile the humoral immunity and cross-reactivity in the dengue patients with different outcomes. The Flaviarrays we fabricated contained 17 Flavivirus antigens with high reproducibility (R-square = 0.96) and low detection limits (172-214 pg). We collected serums from healthy subjects (n = 36) and dengue patients within 7 days after symptom onset (mild dengue (n = 21), hospitalized nonsevere dengue (n = 29), and severe dengue (n = 36)). After profiling the serum antibodies using Flaviarrays, we found that patients with severe dengue showed higher IgG levels against multiple Flavivirus antigens. With logistic regression, we found groups of markers with high performance in distinguishing dengue patients from healthy controls as well as hospitalized from mild cases (AUC > 0.9). We further reported some single markers that were suitable to separate dengue patients from healthy controls (AUC > 0.9) and hospitalized from mild outcomes (AUC > 0.8). Together, Flaviarray is a valuable tool to profile antibody specificities, uncover novel markers for decision-making, and shed some light on early preventions and treatments.Dengue is a viral disease transmitted by Aedes aegypti mosquitoes. According to the World Health Organization, about half of the world's population is at risk of dengue. There are four serotypes of the dengue virus. After infection with one serotype, it will be immune to such a serotype. However, subsequent infection with other serotypes will increase the risk of severe outcomes, e.g., dengue hemorrhagic fever, dengue shock syndrome, and even death. Since severe dengue is challenging to predict and lacks molecular markers, we aim to build a multiplexed Flavivirus protein microarray (Flaviarray) that includes all of the common Flaviviruses to profile the humoral immunity and cross-reactivity in the dengue patients with different outcomes. The Flaviarrays we fabricated contained 17 Flavivirus antigens with high reproducibility (R-square = 0.96) and low detection limits (172-214 pg). We collected serums from healthy subjects (n = 36) and dengue patients within 7 days after symptom onset (mild dengue (n = 21), hospitalized nonsevere dengue (n = 29), and severe dengue (n = 36)). After profiling the serum antibodies using Flaviarrays, we found that patients with severe dengue showed higher IgG levels against multiple Flavivirus antigens. With logistic regression, we found groups of markers with high performance in distinguishing dengue patients from healthy controls as well as hospitalized from mild cases (AUC > 0.9). We further reported some single markers that were suitable to separate dengue patients from healthy controls (AUC > 0.9) and hospitalized from mild outcomes (AUC > 0.8). Together, Flaviarray is a valuable tool to profile antibody specificities, uncover novel markers for decision-making, and shed some light on early preventions and treatments.
AbstractList Dengue is a viral disease transmitted by Aedes aegypti mosquitoes. According to the World Health Organization, about half of the world's population is at risk of dengue. There are four serotypes of the dengue virus. After infection with one serotype, it will be immune to such a serotype. However, subsequent infection with other serotypes will increase the risk of severe outcomes, e.g., dengue hemorrhagic fever, dengue shock syndrome, and even death. Since severe dengue is challenging to predict and lacks molecular markers, we aim to build a multiplexed Flavivirus protein microarray (Flaviarray) that includes all of the common Flaviviruses to profile the humoral immunity and cross-reactivity in the dengue patients with different outcomes. The Flaviarrays we fabricated contained 17 Flavivirus antigens with high reproducibility (R-square = 0.96) and low detection limits (172-214 pg). We collected serums from healthy subjects (n = 36) and dengue patients within 7 days after symptom onset (mild dengue (n = 21), hospitalized nonsevere dengue (n = 29), and severe dengue (n = 36)). After profiling the serum antibodies using Flaviarrays, we found that patients with severe dengue showed higher IgG levels against multiple Flavivirus antigens. With logistic regression, we found groups of markers with high performance in distinguishing dengue patients from healthy controls as well as hospitalized from mild cases (AUC > 0.9). We further reported some single markers that were suitable to separate dengue patients from healthy controls (AUC > 0.9) and hospitalized from mild outcomes (AUC > 0.8). Together, Flaviarray is a valuable tool to profile antibody specificities, uncover novel markers for decision-making, and shed some light on early preventions and treatments.Dengue is a viral disease transmitted by Aedes aegypti mosquitoes. According to the World Health Organization, about half of the world's population is at risk of dengue. There are four serotypes of the dengue virus. After infection with one serotype, it will be immune to such a serotype. However, subsequent infection with other serotypes will increase the risk of severe outcomes, e.g., dengue hemorrhagic fever, dengue shock syndrome, and even death. Since severe dengue is challenging to predict and lacks molecular markers, we aim to build a multiplexed Flavivirus protein microarray (Flaviarray) that includes all of the common Flaviviruses to profile the humoral immunity and cross-reactivity in the dengue patients with different outcomes. The Flaviarrays we fabricated contained 17 Flavivirus antigens with high reproducibility (R-square = 0.96) and low detection limits (172-214 pg). We collected serums from healthy subjects (n = 36) and dengue patients within 7 days after symptom onset (mild dengue (n = 21), hospitalized nonsevere dengue (n = 29), and severe dengue (n = 36)). After profiling the serum antibodies using Flaviarrays, we found that patients with severe dengue showed higher IgG levels against multiple Flavivirus antigens. With logistic regression, we found groups of markers with high performance in distinguishing dengue patients from healthy controls as well as hospitalized from mild cases (AUC > 0.9). We further reported some single markers that were suitable to separate dengue patients from healthy controls (AUC > 0.9) and hospitalized from mild outcomes (AUC > 0.8). Together, Flaviarray is a valuable tool to profile antibody specificities, uncover novel markers for decision-making, and shed some light on early preventions and treatments.
Author Lin, Wei-Hsun
Du, Pin-Xian
Lin, Pei-Chun
Su, Wen-Yu
Tsai, Pei-Shan
Syu, Guan-Da
Wan, Shu-Wen
Lin, Ya-Lan
Keskin, Batuhan Birol
Lee, Nan-Yao
Shih, Hsi-Chang
Ho, Tzong-Shiann
Author_xml – sequence: 1
  givenname: Pei-Shan
  surname: Tsai
  fullname: Tsai, Pei-Shan
– sequence: 2
  givenname: Pin-Xian
  surname: Du
  fullname: Du, Pin-Xian
– sequence: 3
  givenname: Batuhan Birol
  surname: Keskin
  fullname: Keskin, Batuhan Birol
– sequence: 4
  givenname: Nan-Yao
  surname: Lee
  fullname: Lee, Nan-Yao
– sequence: 5
  givenname: Shu-Wen
  surname: Wan
  fullname: Wan, Shu-Wen
– sequence: 6
  givenname: Ya-Lan
  surname: Lin
  fullname: Lin, Ya-Lan
– sequence: 7
  givenname: Wen-Yu
  surname: Su
  fullname: Su, Wen-Yu
– sequence: 8
  givenname: Pei-Chun
  surname: Lin
  fullname: Lin, Pei-Chun
– sequence: 9
  givenname: Wei-Hsun
  surname: Lin
  fullname: Lin, Wei-Hsun
– sequence: 10
  givenname: Hsi-Chang
  surname: Shih
  fullname: Shih, Hsi-Chang
– sequence: 11
  givenname: Tzong-Shiann
  surname: Ho
  fullname: Ho, Tzong-Shiann
– sequence: 12
  givenname: Guan-Da
  surname: Syu
  fullname: Syu, Guan-Da
BookMark eNpNT19LwzAcDDLBbfoNfMijL63506Tp45hOhYqC7nmk6S8z0iWatIV9ezv0wYfjjrvj4BZo5oMHhK4pySlh9FablGuvO_MBh5ybyZLiDM2pYCSTSrHZP32BFil9EkIpoXKO6pXvXRPaI36NwbrO-T0OFt-B3w-A32CE6HoHCW_TKdp0enSji0M69XtwHj87E4OOUR_TJTq3uktw9cdLtN3cv68fs_rl4Wm9qjPNlewzYLSgiqgJjeRVaw0pqRCGG-CEtFJI0zJVTT_ASgum4cxUTcPbEqyQrGBLdPO7-xXD9wCp3x1cMtB12kMY0o6psmBymi7YDzkJVsA
CitedBy_id crossref_primary_10_1016_j_biotechadv_2024_108461
ContentType Journal Article
DBID 7X8
DOI 10.1021/acs.analchem.3c02165
DatabaseName MEDLINE - Academic
DatabaseTitle MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic
Database_xml – sequence: 1
  dbid: 7X8
  name: MEDLINE - Academic
  url: https://search.proquest.com/medline
  sourceTypes: Aggregation Database
DeliveryMethod no_fulltext_linktorsrc
Discipline Engineering
Chemistry
EISSN 1520-6882
GroupedDBID ---
-DZ
-~X
.DC
.K2
23M
4.4
53G
55A
5GY
5RE
5VS
6J9
7X8
7~N
85S
AABXI
AAHBH
ABBLG
ABHFT
ABHMW
ABJNI
ABLBI
ABMVS
ABOCM
ABPPZ
ABQRX
ABUCX
ABUFD
ACBEA
ACGFO
ACGFS
ACGOD
ACIWK
ACJ
ACKOT
ACNCT
ACPRK
ACS
ADHLV
AEESW
AENEX
AFEFF
AFRAH
AGXLV
AHGAQ
ALMA_UNASSIGNED_HOLDINGS
AQSVZ
BAANH
BKOMP
CS3
CUPRZ
D0L
EBS
ED~
F5P
GGK
GNL
IH9
IHE
JG~
KZ1
LMP
P2P
PQQKQ
ROL
RXW
TAE
TN5
UHB
UI2
UKR
VF5
VG9
W1F
WH7
X6Y
XSW
YZZ
ZCA
~02
ID FETCH-LOGICAL-a386t-e2141808180b639dfc07155c3ce300d656cd289c02ef6fecb32c9bb3d7ef56242
IEDL.DBID 7X8
ISICitedReferencesCount 1
ISICitedReferencesURI http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=001082560500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
ISSN 1520-6882
IngestDate Sun Nov 09 12:51:22 EST 2025
IsPeerReviewed true
IsScholarly true
Issue 41
Language English
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-a386t-e2141808180b639dfc07155c3ce300d656cd289c02ef6fecb32c9bb3d7ef56242
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
PQID 2874266394
PQPubID 23479
ParticipantIDs proquest_miscellaneous_2874266394
PublicationCentury 2000
PublicationDate 2023-10-17
PublicationDateYYYYMMDD 2023-10-17
PublicationDate_xml – month: 10
  year: 2023
  text: 2023-10-17
  day: 17
PublicationDecade 2020
PublicationTitle Analytical chemistry (Washington)
PublicationYear 2023
SSID ssj0011016
Score 2.441058
Snippet Dengue is a viral disease transmitted by Aedes aegypti mosquitoes. According to the World Health Organization, about half of the world's population is at risk...
SourceID proquest
SourceType Aggregation Database
StartPage 15217
Title Antibody Profiling of Dengue Severities Using Flavivirus Protein Microarrays
URI https://www.proquest.com/docview/2874266394
Volume 95
WOSCitedRecordID wos001082560500001&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D
hasFullText
inHoldings 1
isFullTextHit
isPrint
link http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LSwMxEA5qBfXgoyq-ieB1a5N0N7snKdXioZaCD3or2SQrC7qru22h_96ZuEsFL4LXIYdkkswjM_k-Qq4ig7Di3Hoy1JCgaAZ3Dvy0J0GqYss5c92ELwM5HIbjcTSqHtzKqq2ytonOUJtc4xv5NeKygzMRUefm49ND1iisrlYUGqukISCUwVMtx8sqAmamDi8VUyQIJeuvc5xdK122FGwVaOa9JTSIAv-XOXY-pr_z39ntku0quqTd7-OwR1Zs1iQbvZrUrUm2fuAP7pNBN5umcW4WdOSou0FI84Te2ux1ZumjhWPuAFepayyg_Tc1T-dpMStxPNJk0gfs51NFoRblAXnu3z317r2KXsFTIgymnuWsw5B4I2zHMHOTaAg3fF8LbUW7bSDQ0wbSMdCNTYLE6lhwHcWxMNImPn4rOSRrWZ7ZI0KFgDgpZJIZZSDf43GYBBq8I4KVCRnxY3JZq20CC8aahMpsPisnS8Wd_GHMKdlEunf0HUyekUYCV9Sek3U9n6ZlceF2_wttCbjd
linkProvider ProQuest
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Antibody+Profiling+of+Dengue+Severities+Using+Flavivirus+Protein+Microarrays&rft.jtitle=Analytical+chemistry+%28Washington%29&rft.au=Tsai%2C+Pei-Shan&rft.au=Du%2C+Pin-Xian&rft.au=Keskin%2C+Batuhan+Birol&rft.au=Lee%2C+Nan-Yao&rft.date=2023-10-17&rft.issn=1520-6882&rft.eissn=1520-6882&rft.volume=95&rft.issue=41&rft.spage=15217&rft_id=info:doi/10.1021%2Facs.analchem.3c02165&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1520-6882&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1520-6882&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1520-6882&client=summon